In 2000, Sinclair et al(2) reported deletions on der(9)t(9;22) including 3′ BCR and 5′ ABL1 in 10–15% of CML patients and suggested that these findings had adverse prognostic significance. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.